Home
Conditions
Blood Protein Disorders

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,037 public trials 564 recruiting studies

Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Active, Not Recruiting

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979

Conditions: Agammaglobulinemia, Blood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +9 more
Locations: Benioff Children's Hospital - Mission Bay San Francisco, California, United States

IMMUNOe Health and Research Centers Centennial, Colorado, United States

Johns Hopkins All Children's Hospital St. Petersburg, Florida, United States

Velocity Clinical Research - MedPharmics - Lafayette Lafayette, Louisiana, United States

View all 21 locations

View Trial Details

Active, Not Recruiting

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03290950

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen Montvale, New Jersey, United States

Memorial Sloan Kettering Commack Commack, New York, United States

View Trial Details

Active, Not Recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

NCT06400238

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +20 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

NCT06360575

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT05734495

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +17 more
Locations: Beth Israel Deaconness Medical Boston, Massachusetts, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

NCT06566547

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: he First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Blood Protein Disorders

Blood Protein Disorders trial results

Related conditions